Matthew Galsky, MD, on the role of PD-L1 testing in previously untreated, locally advanced or mUC

Dr. Galsky, Acting Chief, Division of Hematology and Medical Oncology, Mount Sinai Health System, Director of Genitourinary Medical Oncology, Co-Director, Center of Excellence for Bladder Cancer at Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, shares perspective on the role of PD-L1 testing in previously untreated, locally advanced or metastatic urothelial carcinoma (mUC) as seen in the Phase III IMvigor130 study presented at ASCO GU 2021